Pelthos Therapeutics IncPTHS
Price$20.35

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $43.3MTTM through 30 Jun 2026
Net Income -$86.4MTTM through 30 Jun 2026
Free Cash Flow -$42.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin84.7%
EBITDA Margin-121.9%
Operating Margin-120.0%
Net Margin-199.5%

Returns

-137.8%ROE
-41.1%ROA

Balance Sheet Health

Debt / Equity0.77x
Current Ratio2.69x
Net Debt-$2Mnet cash position
Cash & Equivalents$24.2M

Quality Metrics

Altman Z-Score-1.57
Piotroski F-Score1 / 9
FCF Margin-98.4%
Rule of 40-50.8
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'24'25
FY2025: $16.8M
Diluted EPS-$28.63TTM
'23'24'25
FY2025: $-23.04

Dividend

No dividend

Capital Allocation

R&D Spend$1.3M
Capex Intensity0.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.